

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

LS1034

RRID:CVCL_1382

Type: Cell Line

Proper Citation

RRID:CVCL_1382

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1382

Proper Citation: RRID:CVCL_1382

Description: Cell line LS1034 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Cecum adenocarcinoma

Defining Citation: [PMID:1389533](#), [PMID:1617643](#), [PMID:8464898](#), [PMID:8895552](#), [PMID:9000147](#), [PMID:9000572](#), [PMID:10737795](#), [PMID:11414198](#), [PMID:11526487](#), [PMID:16418264](#), [PMID:16969076](#), [PMID:18258742](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20570890](#), [PMID:20606684](#), [PMID:22460905](#), [PMID:23932154](#), [PMID:24042735](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25926053](#), [PMID:25944804](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28683746](#), [PMID:28854368](#), [PMID:29101300](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LS1034

Synonyms: LS 1034, LS-1034

Cross References: CLO:CLO_0007396, CLO:CLO_0009966, EFO:EFO_0002226, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2158, BCRC:60353, BioGRID_ORCS_Cell_line:711, BioSample:SAMN03472348,

BioSample:SAMN10988322, cancercellines:CVCL_1382, Cell_Model_Passport:SIDM00681, ChEMBL-Cells:ChEMBL3308846, ChEMBL-Targets:ChEMBL2366072, ColonAtlas:LS1034, Cosmic:711266, Cosmic:887236, Cosmic:917486, Cosmic:948850, Cosmic:983741, Cosmic:985655, Cosmic:986015, Cosmic:995409, Cosmic:1043819, Cosmic:1310933, Cosmic:1479603, Cosmic:1609483, Cosmic:1708400, Cosmic:1995489, Cosmic:2760089, Cosmic:2800569, Cosmic-CLP:917486, DepMap:ACH-000252, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:917486, GEO:GSM206519, GEO:GSM463045, GEO:GSM513912, GEO:GSM514298, GEO:GSM784018, GEO:GSM887277, GEO:GSM888352, GEO:GSM1006216, GEO:GSM1006217, GEO:GSM1006218, GEO:GSM1448112, GEO:GSM1670058, GEO:GSM2550008, IARC_TP53:6483, IARC_TP53:21476, IARC_TP53:21741, IGRhCellID:LS1034, KCLB:22158, LiGeA:CCLE_585, LINCS_LDP:LCL-1336, PharmacDB:LS1034_860_2019, PRIDE:PXD005235, PRIDE:PXD005354, PRIDE:PXD005355, PRIDE:PXD030304, Progenetix:CVCL_1382, PubChem_Cell_line:CVCL_1382, Wikidata:Q54903040

ID: CVCL_1382

Record Creation Time: 20220427T220735+0000

Record Last Update: 20260829T234526+0000

Ratings and Alerts

No rating or validation information has been found for LS1034.

No alerts have been found for LS1034.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Lentz RW, et al. (2026) Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model. *Frontiers in oncology*, 16, 1721685.

Gonçalves TJ, et al. (2026) Preventive Effect of Butyrate in Colon Cancer Cell Metabolism. *International journal of molecular sciences*, 27(8).

Li X, et al. (2026) LFPM inhibition of RING1-mediated p53R175H degradation drives oncogenesis in p53R175H-mutant cancers. *Cell death and differentiation*.

Wang R, et al. (2025) Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor. *Cell reports. Medicine*, 6(7), 102213.

Feng J, et al. (2025) A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. *Cancer cell*.

Sogari A, et al. (2024) Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells. *Cell reports. Medicine*, 5(2), 101376.

Bootsma S, et al. (2024) Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases. *Cell reports. Medicine*, 5(5), 101523.

Giarrizzo M, et al. (2024) TR-107, an Agonist of Caseinolytic Peptidase Proteolytic Subunit, Disrupts Mitochondrial Metabolism and Inhibits the Growth of Human Colorectal Cancer Cells. *Molecular cancer therapeutics*, 23(12), 1761.

Kim J, et al. (2022) KS10076, a chelator for redox-active metal ions, induces ROS-mediated STAT3 degradation in autophagic cell death and eliminates ALDH1+ stem cells. *Cell reports*, 40(3), 111077.

Vitiello PP, et al. (2021) Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. *Journal of experimental & clinical cancer research : CR*, 40(1), 15.

McFall T, et al. (2021) Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach. *Cell reports*, 37(11), 110096.

Rozga P, et al. (2020) Novel engineered TRAIL-based chimeric protein strongly inhibits tumor growth and bypasses TRAIL resistance. *International journal of cancer*, 147(4), 1117.

Schulz-Heddergott R, et al. (2018) Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion. *Cancer cell*, 34(2), 298.

Pires AS, et al. (2018) Ascorbic Acid Chemosensitizes Colorectal Cancer Cells and Synergistically Inhibits Tumor Growth. *Frontiers in physiology*, 9, 911.